when will compounded tirzepatide no longer be available FDA ban on tirzepatide: Switch to name brand medications A Guide to Compounded Tirzepatide

Medicare's GLP-1 Bridge Program now offers eligible beneficiaries access to weight loss medications for a $50 monthly copay

Antiobesity medications are recommended in conjunction with lifestyle modifications to manage obesity

The FDA pharmacovigilance data classifies eructation as an "early failure type" event, with a median onset of six days from treatment initiation

Gallbladder complications, including cholecystitis and gallstone formation, have been documented in patients experiencing rapid weight loss, so notify your prescribing physician if you develop severe upper-right abdominal pain

We help you navigate insurance coverage and explore savings programs to reduce costs